Mentor Capital, Inc. Rated A $5/sh Speculative Buy On Immune System Breast Cancer Treatment In FDA Phase I/II Trials

Main Category: Breast Cancer
Also Included In: Clinical Trials / Drug Trials;  Regulatory Affairs / Drug Approvals
Article Date: 02 Nov 2009 - 4:00 PST

email to a friend   printer friendly   view / write opinions   rate article

Mentor Capital, Inc. (Pink Sheets: MNTR) is well poised to be a significant participant in the expanding medical sector of Cancer Immunotherapy with a $5 price objective according to Senior Securities Analyst Howard N. Stillman. That implied 165% gain over the current $1.89/share price, compounds the 88% three-month stock price appreciation already experienced by the Company since it announced its exclusive investment focus on this emerging approach to overcome the historic medical nemesis of cancer.

In any immunotherapy, mild flu-like symptoms are experienced by the patients as compared to the severe side effects experienced after chemotherapy, radiation, or surgical treatments. Mentor Capital's primary investee, Quantum Immunologics, Inc., is conducting FDA authorized Phase I/II trials for its metastatic breast cancer treatment to test the goal of enabling the human immune system to identify and kill breast cancer cells with no harm to other healthy tissue. A 40% selection by late stage breast cancer patients of immunotherapy over chemotherapy projects to $2 Billion in annual revenue. Mentor Capital stepped warrants could raise up to $145 Million to support that commercial introduction of Quantum medical technologies. The Mentor Funding Agreement contemplates "significantly increased investment, or even merger of the parties."

It is interesting to note that the common stock of Dendreon Corporation (DNDN), pursuing a similar technology to treat prostate cancer, has appreciated 1,000% in the past six months of this year. Mr. Stillman concludes, "The MNTR shares at current price levels represent exciting speculative prospects to risk oriented investors seeking material capital gains potential." The entire text of the October 21, 2009 report commissioned by Mentor Capital from Mr. Stillman may be viewed here.

Howard N. Stillman has over 20 years of Wall Street experience and served as Director of Research at two New York Stock Exchange firms. There he was approved by the New York Stock Exchange as a Supervisory Analyst and held membership in the New York Society of Security Analysts. Mr. Stillman earned an MBA in Finance from New York University and taught finance and economics at the college level. He has often been called as an expert witness in investment fraud cases and has participated in over 100 such cases since 1987. Mr. Stillman holds no Mentor Capital nor Quantum Immunologics securities.

Source
Mentor Capital, Inc.